George Blanck - Publications

University of South Florida, Tampa, FL, United States 
Molecular Biology, Cell Biology

36 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2017 Clark NM, Garcia Galindo CA, Patel VK, Parry ML, Stoll RJ, Yavorski JM, Pinkason EP, Johnson EM, Walker CM, Johnson J, Sexton WJ, Coppola D, Blanck G. The human, F-actin-based cytoskeleton as a mutagen sensor. Cancer Cell International. 17: 121. PMID 29255378 DOI: 10.1186/s12935-017-0488-5  0.56
2016 Parry ML, Blanck G. Flat cells come full sphere: Are mutant cytoskeletal-related proteins oncoprotein-monsters or useful immunogens? Human Vaccines & Immunotherapeutics. 12: 120-3. PMID 26225584 DOI: 10.1080/21645515.2015.1073428  1
2015 Fawcett TJ, Parry ML, Blanck G. A Novel Approach to Evaluating Cancer Driver Gene Mutation Densities: Cytoskeleton-related Gene Candidates. Cancer Genomics & Proteomics. 12: 283-90. PMID 26543077  1
2015 Blazekovic F, Odukoya D, Butler SN, Mauro JA, Ramsamooj M, Puleo E, Szekeres K, Dana D, Kumar S, Ragupathi G, Blanck G. HLA-DR peptide occupancy can be regulated with a wide variety of small molecules. Human Vaccines & Immunotherapeutics. 0. PMID 26453454 DOI: 10.1080/21645515.2015.1089370  1
2015 Butler SN, Blanck G. Immunoscoring by correlating MHC class II and TCR expression: high level immune functions represented by the KIRP dataset of TCGA. Cell and Tissue Research. PMID 26293619 DOI: 10.1007/s00441-015-2261-1  1
2015 Frangione ML, Lockhart JH, Morton DT, Pava LM, Blanck G. Anticipating designer drug-resistant cancer cells. Drug Discovery Today. 20: 790-3. PMID 25697478 DOI: 10.1016/j.drudis.2015.02.005  1
2015 Lloyd MC, Szekeres K, Brown JS, Blanck G. Class II transactivator expression in melanoma cells facilitates T-cell engulfment. Anticancer Research. 35: 25-9. PMID 25550531  1
2015 Parry ML, Ramsamooj M, Blanck G. Big genes are big mutagen targets: a connection to cancerous, spherical cells? Cancer Letters. 356: 479-82. PMID 25451318 DOI: 10.1016/j.canlet.2014.09.044  1
2015 Ford SA, Blanck G. Signal persistence and amplification in cancer development and possible, related opportunities for novel therapies. Biochimica Et Biophysica Acta. 1855: 18-23. PMID 25450826 DOI: 10.1016/j.bbcan.2014.11.001  1
2015 Mauro JA, Butler SN, Ramsamooj M, Blanck G. Copy number loss or silencing of apoptosis-effector genes in cancer. Gene. 554: 50-7. PMID 25307873 DOI: 10.1016/j.gene.2014.10.021  1
2014 Lloyd MC, Burke N, Kalantarpour F, Niesen MI, Hall A, Pennypacker K, Citron B, Pick CG, Adams V, Das M, Mohapatra S, Cualing H, Blanck G. QUANTITATIVE MORPHOLOGICAL AND MOLECULAR PATHOLOGY OF THE HUMAN THYMUS CORRELATE WITH INFANT CAUSE OF DEATH. Technology and Innovation. 16: 55-62. PMID 25309682 DOI: 10.3727/194982414X13971392823398  0.92
2014 Szekeres K, Koul R, Mauro J, Lloyd M, Johnson J, Blanck G. An Oct-1-based, feed-forward mechanism of apoptosis inhibited by co-culture with Raji B-cells: towards a model of the cancer cell/B-cell microenvironment. Experimental and Molecular Pathology. 97: 585-9. PMID 25236570 DOI: 10.1016/j.yexmp.2014.09.010  1
2013 Cronin K, Escobar H, Szekeres K, Reyes-Vargas E, Rockwood AL, Lloyd MC, Delgado JC, Blanck G. Regulation of HLA-DR peptide occupancy by histone deacetylase inhibitors. Human Vaccines & Immunotherapeutics. 9: 784-9. PMID 23328677 DOI: 10.4161/hv.23085  1
2013 Pillai S, Szekeres K, Lawrence NJ, Chellappan SP, Blanck G. Regulation of interlocking gene regulatory network subcircuits by a small molecule inhibitor of retinoblastoma protein (RB) phosphorylation: cancer cell expression of HLA-DR. Gene. 512: 403-7. PMID 23041127 DOI: 10.1016/j.gene.2012.09.092  1
2009 Coppola D, Parikh V, Boulware D, Blanck G. Substantially reduced expression of PIAS1 is associated with colon cancer development Journal of Cancer Research and Clinical Oncology. 135: 1287-1291. PMID 19288270 DOI: 10.1007/s00432-009-0570-z  1
2009 Niesen MI, Osborne AR, Lagor WR, Zhang H, Kazemfar K, Ness GC, Blanck G. Technological advances in the study of HLA-DRA promoter regulation: extending the functions of CIITA, Oct-1, Rb, and RFX. Acta Biochimica Et Biophysica Sinica. 41: 198-205. PMID 19280058 DOI: 10.1093/abbs/gmp002  1
2009 Niesen MI, Blanck G. Rescue of major histocompatibility-DR surface expression in retinoblastoma-defective, non-small cell lung carcinoma cells by the MS-275 histone deacetylase inhibitor. Biological & Pharmaceutical Bulletin. 32: 480-2. PMID 19252299 DOI: JST.JSTAGE/bpb/32.480  0.92
2009 Kazemfar K, Chen R, Nicholson K, Coppola D, Zhou JM, Chen X, Wei S, Blanck G. Combined IL-8 and TGF-beta blockade efficiently prevents neutrophil infiltrates into an A549-cell tumor. Immunology Letters. 122: 26-9. PMID 19056425 DOI: 10.1016/j.imlet.2008.10.010  0.56
2009 Xu L, Niesen MI, Blanck G. Linkage of a tumor immune function and cell cycle de-regulation via a gene regulatory network subcircuit. Molecular Immunology. 46: 569-75. PMID 18952290 DOI: 10.1016/j.molimm.2008.07.035  0.92
2006 Palubin KM, Goodwin BL, Niesen MI, Le EA, Osborne AR, Blanck G. A direct mechanistic link between growth control and a tumor cell immune function: increased interleukin-8 secretion accounts for elimination of Oct-1 antisense transformants from scid mice. Anticancer Research. 26: 1733-8. PMID 16827100  1
2006 Osborne AR, Zhang H, Blanck G. Oct-1 DNA binding activity unresponsive to retinoblastoma protein expression prevents MHC class II induction in a non-small cell lung carcinoma cell line. Molecular Immunology. 43: 710-6. PMID 16360016 DOI: 10.1016/j.molimm.2005.03.013  1
2005 Le E, Zhang H, Blanck G. CIITA transformation rescues the apoptotic function of MHC class II in melanoma cells. Anticancer Research. 25: 3889-92. PMID 16312044  1
2005 Niesen MI, Osborne AR, Yang H, Rastogi S, Chellappan S, Cheng JQ, Boss JM, Blanck G. Activation of a methylated promoter mediated by a sequence-specific DNA-binding protein, RFX. The Journal of Biological Chemistry. 280: 38914-22. PMID 16166088 DOI: 10.1074/jbc.M504633200  1
2004 Osborne AR, Zhang H, Fejer G, Palubin KM, Niesen MI, Blanck G. Oct-1 maintains an intermediate, stable state of HLA-DRA promoter repression in Rb-defective cells: an Oct-1-containing repressosome that prevents NF-Y binding to the HLA-DRA promoter. The Journal of Biological Chemistry. 279: 28911-9. PMID 15105429 DOI: 10.1074/jbc.M403118200  1
2003 Eason DD, LeBron C, Coppola D, Moscinski LC, Livingston S, Sutton ET, Blanck G. Development of CD30+ lymphoproliferative disease in mice lacking interferon regulatory factor-1. Oncogene. 22: 6166-76. PMID 13679855 DOI: 10.1038/sj.onc.1206563  1
2003 Xi H, Blanck G. The IRF-2 DNA binding domain facilitates the activation of the class II transactivator (CIITA) type IV promoter by IRF-1. Molecular Immunology. 39: 677-84. PMID 12493643 DOI: 10.1016/S0161-5890(02)00214-6  1
2001 Osborne A, Zhang H, Yang W, Seto E, Blanck G. Histone deacetylase activity represses gamma interferon-inducible HLA-DR gene expression following the establishment of a DNase, I-hypersensitive chromatin conformation Molecular and Cellular Biology. 21: 6495-6506. PMID 11533238 DOI: 10.1128/MCB.21.19.6495-6506.2001  1
2001 Eason DD, Coppola D, Livingston S, Shepherd AT, Blanck G. Loss of MHC class II inducibility in hyperplastic tissue in Rb-defective mice. Cancer Letters. 171: 209-14. PMID 11520605  0.92
2001 Xi H, Goodwin B, Shepherd AT, Blanck G. Impaired class II transactivator expression in mice lacking interferon regulatory factor-2. Oncogene. 20: 4219-27. PMID 11464288 DOI: 10.1038/sj.onc.1204556  0.92
2001 Goodwin BL, Xi H, Tejiram R, Eason DD, Ghosh N, Wright KL, Nagarajan U, Boss JM, Blanck G. Varying functions of specific major histocompatibility class II transactivator promoter III and IV elements in melanoma cell lines. Cell Growth & Differentiation : the Molecular Biology Journal of the American Association For Cancer Research. 12: 327-35. PMID 11432807  1
2001 Eason DD, Blanck G. High level class II trans-activator induction does not occur with transient activation of the IFN-gamma signaling pathway. Journal of Immunology (Baltimore, Md. : 1950). 166: 1041-8. PMID 11145683  0.92
2000 Zhang H, Wei S, Sun J, Coppola D, Zhong B, Wu GD, Goodwin B, Sebti S, Djeu JY, Blanck G. Retinoblastoma protein activation of interleukin 8 expression inhibits tumor cell survival in nude mice. Cell Growth & Differentiation : the Molecular Biology Journal of the American Association For Cancer Research. 11: 635-9. PMID 11149598  1
2000 Xi H, Blanck G. Interferon regulatory factor-2 point mutations in human pancreatic tumors. International Journal of Cancer. 87: 803-8. PMID 10956389 DOI: 10.1002/1097-0215(20000915)87:6<803::AID-IJC7>3.0.CO;2-E  1
1999 Xi H, Eason DD, Ghosh D, Dovhey S, Wright KL, Blanck G. Co-occupancy of the interferon regulatory element of the class II transactivator (CIITA) type IV promoter by interferon regulatory factors 1 and 2. Oncogene. 18: 5889-903. PMID 10557076 DOI: 10.1038/sj.onc.1202969  1
1999 Zhang H, Shepherd AT, Eason DD, Wei S, Diaz JI, Djeu JY, Wu GD, Blanck G. Retinoblastoma protein expression leads to reduced Oct-1 DNA binding activity and enhances interleukin-8 expression. Cell Growth & Differentiation : the Molecular Biology Journal of the American Association For Cancer Research. 10: 457-65. PMID 10437913  1
1999 Eason DD, Shepherd AT, Blanck G. Interferon regulatory factor 1 tryptophan 11 to arginine point mutation abolishes DNA binding. Biochimica Et Biophysica Acta. 1446: 140-4. PMID 10395927  0.92
Show low-probability matches.